Tamoxifen tablet survey a mixed bag for Dara

|By:, SA News Editor

Dara Biosciences (DARA), which provides a liquid version of the Tamoxifen treatment for breast cancer, finds that the adherence of patients to the tablet form "is less than optimal."

In a survey, 14% of respondents said they miss two or more Tamoxifen doses a month, while 8% had swallowing difficulties.

Seven percent said a liquid version of Tamoxifen would boost their compliance and 22% said they'd be willing to try it.

Shares are +3.7% premarket. (PR)